

Telix, Nihon collaborate on renal cancer imaging for Japanese market

20 August 2018 | News

The agreement between Telix and NMP is focused on Telix's TLX250 imaging program for renal cancer with Positron Emission Tomography (PET).



Singapore – Telix Pharmaceuticals Limited, a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), and Nihon Medi-Physics Ltd, a manufacturer and supplier of radiopharmaceuticals and related products in Japan, have announced that they have entered into a memorandum of understanding (MoU) for a commercial partnership in renal cancer imaging for the Japanese market.

The agreement between Telix and NMP is focused on Telix's TLX250 imaging program for renal cancer with Positron Emission Tomography (PET). Under the terms of the agreement, Telix and NMP will work together to establish a commercial partnership for TLX250 in Japan, with the objective of appointing NMP as an exclusive partner for the product in Japan. NMP will also support Telix in the near-term goal of including Japanese patients in Telix's global Phase III development program for TLX250.

Telix Pharmaceuticals Japan President, Dr. Shintaro Nishimura stated, “NMP is a leading company in the Japanese radiopharmaceutical landscape with a strong track record of stable supply of PET imaging agents. As we develop our Japanese regulatory strategy for TLX250, we are pleased to have the experience and guidance of NMP.”